Compare BBIO & NTNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBIO | NTNX |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 14.1B |
| IPO Year | 2019 | 2016 |
| Metric | BBIO | NTNX |
|---|---|---|
| Price | $74.32 | $53.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 16 |
| Target Price | ★ $78.43 | $74.20 |
| AVG Volume (30 Days) | 1.9M | ★ 4.3M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | $353,780,000.00 | ★ $2,617,547,000.00 |
| Revenue This Year | $127.64 | $14.23 |
| Revenue Next Year | $78.38 | $14.00 |
| P/E Ratio | ★ N/A | $70.22 |
| Revenue Growth | ★ 62.46 | 17.45 |
| 52 Week Low | $28.10 | $46.12 |
| 52 Week High | $78.59 | $83.36 |
| Indicator | BBIO | NTNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 52.11 |
| Support Level | $71.19 | $50.27 |
| Resistance Level | $75.57 | $54.11 |
| Average True Range (ATR) | 2.44 | 1.38 |
| MACD | -0.65 | 0.72 |
| Stochastic Oscillator | 38.54 | 79.07 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.